Download Files:
Products Details
Product Description
– Dehydrovomifoliol is a AKT/mTOR dual inhibitor. Dehydrovomifoliol reduces lipid accumulation and lipogenesis by inhibiting the AKT/mTOR signaling pathway. Dehydrovomifoliol is used in nonalcoholic fatty liver disease research (NAFLD) .
Web ID
– HY-137996
Shipping
– Room temperature
Molecular Formula
– C13H18O3
References
– [1]Ma
J, et al. Dehydrovomifoliol Alleviates Nonalcoholic Fatty
Liver Disease via the E2F1/AKT/mTOR Axis: Pharmacophore Modeling and Molecular
Docking Study. Evid Based Complement Alternat Med. 2023 Feb 1;2023:9107598.
CAS Number
– 39763-33-2
Molecular Weight
– 222.28
SMILES
– CC(/C=C/[C@](C(C)(C1)C)(C(C)=CC1=O)O)=O
Clinical Information
– No Development Reported
Research Area
– Metabolic Disease
Solubility
– 10 mM in DMSO
Target
– Akt;mTOR
Pathway
– PI3K/Akt/mTOR
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
